NCT05200273View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

PHASE1UnknownINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2023

Conditions

Advanced or Metastatic Solid TumorsMalignancyMetastasis

Interventions

DRUG

AK114

AK114 administered by subcutaneous injection

Trial Locations (1)

Unknown

Ashford Cancer Centre, Kurralta Park

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY

NCT05200273 - A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 | Biotech Hunter | Biotech Hunter